Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.
Quiros-Roldan E, Torti C, Lapadula G, Ladisa N, Micheli V, Patroni A, Cusato M, Pierotti P, Tirelli V, Uccelli MC, Di Giambenedetto S, Castelnuovo F, Gargiulo F, Manca N, Carosi G; RADAR-Master Study Group. Quiros-Roldan E, et al. Among authors: di giambenedetto s. AIDS Patient Care STDS. 2007 Feb;21(2):92-9. doi: 10.1089/apc.2005.0037. AIDS Patient Care STDS. 2007. PMID: 17328658 Clinical Trial.
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
Zaccarelli M, Perno CF, Forbici F, Cingolani A, Liuzzi G, Bertoli A, Trotta MP, Bellocchi MC, Di Giambenedetto S, Tozzi V, Gori C, D'Arrigo R, De Longis P, Noto P, Girardi E, De Luca A, Antinori A. Zaccarelli M, et al. Among authors: di giambenedetto s. Antivir Ther. 2003 Feb;8(1):51-6. Antivir Ther. 2003. PMID: 12713064
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.
De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, Bertoli A, Liuzzi G, Narciso P, Murri R, Ammassari A, Perno CF, Antinori A. De Luca A, et al. Among authors: di giambenedetto s. J Infect Dis. 2003 Jun 15;187(12):1934-43. doi: 10.1086/375355. Epub 2003 May 22. J Infect Dis. 2003. PMID: 12792870 Clinical Trial.
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations.
Torti C, Quiros-Roldan E, Regazzi-Bonora M, De Luca A, Lo Caputo S, Di Giambenedetto S, Patroni A, Villani P, Micheli V, Carosi G; Resistance and Dosage Adapted Regimens Study Group of the MASTER Cohort. Torti C, et al. Among authors: di giambenedetto s. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):324-6. doi: 10.1097/00126334-200403010-00017. J Acquir Immune Defic Syndr. 2004. PMID: 15076251 Clinical Trial. No abstract available.
Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
De Luca A, Cozzi-Lepri A, Perno CF, Balotta C, Di Giambenedetto S, Poggio A, Pagano G, Tositti G, Piscopo R, Del Forno A, Chiodo F, Magnani G, d'Arminio Monforte A; ICoNA drug resistance study group; ICoNA study group. De Luca A, et al. Among authors: di giambenedetto s. Antivir Ther. 2004 Oct;9(5):743-52. Antivir Ther. 2004. PMID: 15535412
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A; International Study Group on CD4-monitored Treatment Interruptions. Mussini C, et al. Among authors: di giambenedetto s. AIDS. 2005 Feb 18;19(3):287-94. AIDS. 2005. PMID: 15718839
306 results